Technical Data
Interferon-inducible T Cell Alpha Chemoattractant, Recombinant, Human (I-TAC)
Molecular Biology Storage: -20CShipping: Blue Ice
CXCL11 (ITAC) is one of three chemokines known to bind the receptor CXCR3, the two others being CXCL9 (Mig) and CXCL10 (IP-10). CXCL11 differs from the other CXCR3 ligands in both the strength and the particularities of its receptor interactions: It has a higher affinity, is a stronger agonist, and behaves differently when critical N-terminal residues are deleted CXCL11 takes on the canonical chemokine fold but exhibits greater conformational flexibility than has been observed for related chemokines under the same sample conditions. Unlike related chemokines such as IP-10 and IL-8, ITAC does not appear to form dimers at millimolar concentrations. The origin for this behavior can be found in the solution structure, which indicates a beta-bulge in beta-strand 1 that distorts the dimerization interface used by other CXC chemokines.

Recombinant Human I-TAC (Interferon-inducible T-cell alpha chemoattractant) produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 73 amino acids and having a molecular mass of 8300 Dalton. Recombinant Human I-TAC is purified by proprietary chromatographic techniques.

Amino Acid Sequence:
The sequence of the first five N-terminal amino acids was determined and was found to be, Phe-Pro-Met-Phe-Lys.

Dimers and Aggregates:
Less than 1% as determined by silver-stained SDS-PAGE gel analysis.

Biological Activity:
Recombinant Human I-TAC is fully biologically active when compared to standard. The Activity is calculated by the ability to chemoattract IL-2 activated T-cells using a concentration of 0.1-10 ng/ml.

0.1ng/ug (IEU/ug) of Human I-TAC.

Protein Content:
Protein quantitation was carried out by two independent methods:
1. UV spectroscopy at 280 nm .
2. Analysis by RP-HPLC, using a calibrated solution of Human I-TAC as a Reference Standard.

It is recommended to reconstitute the lyophilized Recombinant Human I-TAC in sterile 18M -cm H2O not less than 100g/ml, which can then be further diluted to other aqueous solutions.

Lyophilized I-TAC although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution I-TAC should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Molecular Weight:
Source: E. coli
Purity: 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.
Concentration: ~1mg/ml
Form: Supplied as a lyophilized powder without additives.

Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
1. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11.
Blood 2006 May 15;107(10):3821-31
2. The chemokines CXCL9, CXCL10, and CXCL11 differentially stimulate G alpha i-independent signaling and actin responses in human intestinal myofibroblasts.
J Immunol 2005 Oct 15;175(8):5403-11
3. Interferon-alpha and -beta differentially regulate osteoclastogenesis: role of differential induction of chemokine CXCL11 expression.
Proc Natl Acad Sci U S A 2005 Aug 16;102(33):11917-22
4. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
J Immunother 2005 Jul-Aug;28(4):343-51
5. Increased expression of CXCR3 and CCR5 on memory CD4+ T-cells migrating into the cerebrospinal fluid of patients with neuroborreliosis: the role of CXCL10 and CXCL11.
J Neuroimmunol 2005 Jun;163(1-2):128-34
6. CXCL11 is involved in leucocyte recruitment to the central nervous system in neuroborreliosis.
J Neurol 2005 Jul;252(7):820-3

Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.